SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Texas Biotech (TXB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Dauntless who wrote (738)2/6/1999 11:59:00 PM
From: Cacaito  Read Replies (2) of 834
 
News from Roche, Refludan (Novastan competitor in the HiT market)
10,000 patients in a prospective study with placebo control (not historical controls) completed and shown effective for unstable angina to decrease infarcts/mortality.

Plus side: Novastan once approved for HiT, could be used off label for angina and/or stroke increasing the possibilities beyond the tiny HIT market.

Negative side: A proven drug like Refludan with strong data will give more problems for Novastan already rejected data.

A new study will be of long duration and expensive (either for HIT or stroke or angina).

The FDA will not have a rush for approving a Refludan similar since the need is fulfill.

There are many more drugs in angina, yes they are not cheaper but they are proven effective.

Not many effective drugs in Stroke, maybe they should go after this indication from the start but they try to shortcut via HIT. So far the strategy is not paying.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News